10% Owner Sells Over $494K in Clene Inc. Stock Amidst Going Concern Doubts
CLNN has more than doubled off its 52-week low of $2.28.
Summary
Ugwumba Chidozie, a 10% owner of Clene Inc. (CLNN), sold 100,997 shares totaling $494,012 in open market transactions, continuing a pattern of insider distribution.
Key Events · Ownership and Investor Activity · CLNN
-
Significant Insider Sale
Ugwumba Chidozie, a 10% owner, sold 100,997 shares of Clene Inc. common stock for a total of $494,012.18 in open market transactions.
-
Follows Prior Intent to Sell
These sales occurred between March 27-31, 2026, following a Form 144 filed on March 24, 2026, by Symbiosis II LLC, indicating an intent to sell 82,212 shares.
-
Context of Going Concern Doubt
The sale takes place shortly after the company's 10-K filing on March 17, 2026, which expressed substantial doubt about its ability to continue as a going concern.
Analysis · CLNN · Life Sciences
This significant sale by a 10% owner, Ugwumba Chidozie (via SymBiosis II, LLC), represents a notable distribution of shares. The transactions occurred between March 27 and March 31, 2026, following a Form 144 filing on March 24, 2026, which indicated an intent to sell. While 10% owner sales are often for portfolio rebalancing, this transaction occurs in the context of Clene Inc.'s recent 10-K, which raised substantial doubt about its ability to continue as a going concern. This ongoing insider selling, totaling over $494,000, could be interpreted negatively by investors, especially given the company's financial uncertainties.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $4.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.1M. The 52-week trading range was $2.28 to $13.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.